SCHEMBL15049103

SCHEMBL15049103

CNCCNc1nc(-c2ccc(C)cc2)sc1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.62
▸ GAA P10253 3/20 0.62
▸ KDM4E B2RXH2 2/20 0.62
▸ SMN1; SMN2 Q16637 4/20 0.49
▸ NPC1 O15118 2/20 0.49
▸ POLB P06746 1/20 0.49
▸ TRPM8 Q7Z2W7 1/20 0.45
▸ TARBP2 Q15633 1/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ MAPT P10636 4/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ HPGD P15428 2/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ CDC7 O00311 2/20 0.42
▸ DBF4 Q9UBU7 2/20 0.42
▸ LMNA P02545 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ XDH P47989 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28246572 0.89 RAB9A (0.61) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL28245733 0.88 GAA (0.46) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL15049277 0.87 GAA (0.58) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL15049166 0.85 TRPM8 (0.62) RAB9AGAAKDM4ETRPM8MAPT
SCHEMBL892234 0.77 RAB9A (1.00) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL15049072 0.76 TRPM8 (0.64) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL28245821 0.76 CDC7 (0.57) KDM4ETRPM8MAPTCDC7DBF4
SCHEMBL27997095 0.75 GAA (0.43) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL28245757 0.74 RAB9A (0.56) RAB9AGAAKDM4ESMN1; SMN2NPC1
SCHEMBL874365 0.74 GAA (0.47) RAB9AGAAKDM4ESMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 — — EP claimed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 — — US claimed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 — — US claimed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 — — US claimed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 — — US claimed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 — — EP claimed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 — — WO claimed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 — — EP claimed
EP-2793883-B1 TRPM8 ANTAGONISTS DOMPE FARM SPA (IT) 2018-04-18 — — EP disclosed
US-9856246-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2018-01-02 — — US disclosed
US-20170129881-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-05-11 — — US disclosed
US-9585875-B2 TRPM8 antagonists DOMPÉ FARMACEUTICI S.P.A. (IT) 2017-03-07 — — US disclosed
US-20140371276-A1 TRPM8 ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-12-18 — — US disclosed
EP-2793883-A1 TRPM8 ANTAGONISTS Dompe' S.p.A. (IT) 2014-10-29 — — EP disclosed
WO-2013092711-A1 TRPM8 ANTAGONISTS DOMPE' S.P.A. (IT) 2013-06-27 — — WO disclosed
EP-2606888-A1 Trpm8 antagonists Dompe' S.P.A. (IT) 2013-06-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170129881-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM5 RAB9A 783/4885GAA 3391/4885KDM4E 4303/4885
US-20140371276-A1 TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPV1 RAB9A 537/4885GAA 3732/4885KDM4E 4283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback